<DOC>
	<DOCNO>NCT00879060</DOCNO>
	<brief_summary>Hypertrophic Cardiomyopathy ( HCM ) common genetic cardiomyopathy remain leading cause sudden cardiac death young people important cause heart failure symptom death age . In HCM , pathological remodeling leave ventricle involve myocardial fibrosis likely major contributor cardiac dysfunction also nidus generation ventricular arrhythmia . Serum marker collagen turnover show reliably reflect magnitude myocardial fibrosis variety cardiovascular disease . In addition , aldosterone antagonist drug show decrease fibrous tissue formation myocardium certain pathologic cardiovascular state aldosterone production increase . In HCM , aldosterone production up-regulated implicated formation myocardial fibrosis . Therefore , specific aim proposal : 1. ass serum marker collagen turnover baseline correlate finding variety clinical morphologic disease parameter 2. examine effect 12-month treatment aldosterone antagonist spironolactone magnitude fibrosis measure serum marker collagen turnover well change clinical morphologic disease parameter . The result proposal offer important insight clinical significance myocardial fibrosis primary genetic cardiomyopathy . The demonstration spironolactone decrease fibrosis improve clinical course would provide rational large multicenter clinical trial evaluate novel therapy improve clinical outcome patient HCM .</brief_summary>
	<brief_title>Clinical Therapeutic Implications Fibrosis Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Hypertrophic cardiomyopathy 2 . Able swallow pill 3 . No prior septal reduction therapy 4 . Negative serum hCG pregnancy test 1 . Unable unwilling perform treadmill cardiopulmonary exercise test 2 . Prior surgical myectomy alcohol septal ablation 3 . Known suspected infiltrative glycogen storage disease 4 . Significant coronary artery disease , define atherosclerotic coronary artery narrow &gt; 70 % luminal diameter coronary angiography 5 . Severe obstructive pulmonary disease , define forced expiratory volume 1 second ( FEV1 ) &lt; 50 % predict . 6 . Prior intolerance adverse reaction aldosterone receptor antagonist . 7 . History hyper hypoaldosteronism 8 . Baseline serum potassium &gt; 5.0 mmol/L . 9 . Calculated creatinine clearance &lt; 30 ml/min use CockcroftGault formula . 10 . Pregnant breast feed 11 . Poorly control systemic hypertension , define systolic blood pressure ≥150 mmHg diastolic pressure ≥100 mmHg , 2 clinic visit . 12 . Known condition associate elevated serum concentration PIIINP ( e.g. , chronic liver disease , diabetes mellitus , tumor , pulmonary fibrosis , bone rheumatoid disease , extensive wound ) PINP ( e.g. , alcoholic liver disease , metabolic bone disease , thyroid disorder ) , include recent trauma ( ≤2 week ) surgery ( ≤6 month ) 13 . Taking drug know directly influence collagen metabolism include , amiodorone , ACE angiotensin II inhibitor , aldosterone antagonist , statin , glucocorticoid estrogens 14 . Patients ICDs/pacemakers recruit study , exclude CMR component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Fibrosis</keyword>
	<keyword>Hypertrophic cardiomyopathy</keyword>
	<keyword>MRI</keyword>
	<keyword>To evaluate efficacy spironolactone decrease myocardial fibrosis Hypertrophic cardiomyopathy</keyword>
</DOC>